The Patent Finder

Prothena Biosciences Limited

37 patents currently held · Updated Nov 17, 2026
26 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

Previously recorded as Neotope Biosciences Limited (to 2015)

7
Ending by 2030
Dec 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 19, 2026
    The maintenance fee for Treatment and Delay of Outset of Synucleinopathic and Amyloidogenic Disease (US 9,034,337) comes due Nov 19, 2026. Unpaid by May 19, 2027, it lapses early.
  • 2 fees due Jan 4 to 28, 2027 · next Jan 4
  • 1 fee due Apr 22, 2027
    The maintenance fee for Humanized Antibodies That Recognize Alpha-Synuclein (US 10,450,369) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
  • 2 fees due Jun 24 to 30, 2027 · next Jun 24
  • 1 fee due Sep 12, 2027
    The maintenance fee for Antibodies Recognizing Tau (US 11,926,659) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
  • 1 fee due Oct 16, 2027
    The maintenance fee for Antibodies recognizing tau (US 11,958,896) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 3 of the patents on this record were granted since Aug 19, 2026
  • 1 term has ended since Aug 19, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,697,082Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
In force
 · Medium confidence
In forceMedium confidence
US 9,034,337Treatment and Delay of Outset of Synucleinopathic and Amyloidogenic Disease
In force
 · Medium confidence
In forceMedium confidence
US 8,506,959Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
In force
 · High confidence
In forceHigh confidence
US 8,268,973Anti-amyloid antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,404,815Chimeric, Humanized, or Human Antibody 2A4
In force
 · High confidence
In forceHigh confidence
US 8,636,981Detection of Amyloid Deposits Using Anti-Amyloid Antibodies
In force
 · Medium confidence
In forceMedium confidence
US 7,928,203Chimeric, Humanized, or Human Antibody 2A4
In force
 · High confidence
In forceHigh confidence
US 9,089,529Antibody formulations and methods
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,884,020Antibody formulations and methods for treating AL amyloidosis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,517,830Antibody formulations and methods
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 37 patents shown.
Pro members see all 37.
Pro members: see all 37 patents
Also on record, not counted in the 37: 26 patents in force now held by others · 30 lapsed for an unpaid fee · 9 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

15 pending · 12 abandoned · 26 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited